Early relapse in a case of primary bone marrow diffuse large B-cell lymphoma treated with rituximab-CHOP.

about

Early relapse in a case of primary bone marrow diffuse large B-cell lymphoma treated with rituximab-CHOP.

Item

http://www.wikidata.org/entity/Q40063229

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Early relapse in a case of pri ...... a treated with rituximab-CHOP.

@en

type

Item

label

Early relapse in a case of pri ...... a treated with rituximab-CHOP.

@en

prefLabel

Early relapse in a case of pri ...... a treated with rituximab-CHOP.

@en

P1476

Early relapse in a case of pri ...... a treated with rituximab-CHOP.

@en

P2093

Guang-Yu Zhou

http://www.w3.org/2001/XMLSchema#string

Wanning Wang

http://www.w3.org/2001/XMLSchema#string

Wenlong Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance

Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.

Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.

Primary bone marrow diffuse large B cell lymphoma: a case series and review.

TP53 dysfunction in diffuse large B-cell lymphoma.

Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.

P304

379-385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2017-0005

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28357915

http://www.w3.org/2001/XMLSchema#string